Alan Gray Email & Phone Number

Macungie, PA, US

Macungie, PA

• Founded and lead a specialized consulting firm focused on oncology commercial strategy and market access.
• Developed and implemented a U.S.-focused commercialization action plan for an emerging medical device manufacturer, securing board, CEO, and CCO approval.
• Formulated key scientific messaging concepts and obtained strategic input from urologists and payers to guide the commercialization plan.
• Designed and executed a Key Opinion Leader (KOL) engagement strategy and major conference plan (American Urology Association) to facilitate high-level scientific and commercial discussions.
• Advanced the value proposition framework with targeted messages and emerging data, and conducted payer testing for actionable insights.
• Led a medical communications workshop that enhanced the oncology product platform.

Greater Philadelphia

• Led a team of three in developing and executing U.S. and global market access and commercial strategies for pharmaceutical and biotech clients, including Revolution Medicine, ProKidney, AstraZeneca, Ocelet Bio.
• Oversaw services including value propositions, pre-approval information exchange (PIE) presentations, pricing strategies, and market research.
• Achieved an annual income stream of $1.3M, a 40% increase from the previous year, contributing to over 50% of total revenue for the $2.1M commercial consulting practice.
• Project 1: Secured and executed a $225,000 engagement for a biologic treatment aimed at reducing kidney failure risk, providing market insights and strategy recommendations from nephrologists and patients.
• Project 2: Managed a $120,000 engagement to develop the value proposition and U.S. payer engagement strategy for a drug targeting paroxysmal supraventricular tachycardia (PSVT).
• Project 3: Directed a $185,000 project focusing on health economics development and testing with EU national advisors (Germany, UK, France) for an asset targeting RAS mutated tumors.

Greater Philadelphia

• Led a team of four in developing oncology-focused market access and commercial strategy initiatives for major and emerging pharmaceutical and biotech companies, including Aveo Pharmaceuticals, AbbVie, Incyte.
• Generated over $3.0M in revenue through strategic initiatives and client engagements.
• Developed value propositions, pre-approval information exchange (PIE) presentations, pricing strategies, and contracting frameworks.
• Executed comprehensive market research to inform strategic decisions and client recommendations.
• Directed strategic planning and management of the market access insights practice, including team development and practice operations.
• Oversaw new business development and client management.

Yardley, PA

• Led a 10-person US-based insights practice team in delivering market research and consulting projects for major pharmaceutical and biotech clients, including Pfizer, GSK, Ferring, AstraZeneca, and Janssen.
• Generated an annual income of $2.3M, representing a 20% increase from the previous year and over 50% of the total revenue of $4.1M in commercial consulting.
• Managed strategic planning and operations of the practice, including team development, practice management, and client engagement.
• Oversaw new business development and ensured successful execution of deliverables for high-profile pharmaceutical companies.
• Developed and implemented the “Oncology 101” training program to enhance team understanding of drug commercialization processes for oncology therapeutics.

New York, NY

• Managed a 5-person US-based consulting team to deliver oncology-focused market research and consulting projects for pharmaceutical, biotech, and major healthcare clients, including Amgen, EMD (Merck/Millipore), GSK.
• Achieved an annual income stream of $2.8M, marking a 20% increase from the previous year and contributing over 30% of the total revenue within a $6.1M commercial consulting practice.
• Executed consulting engagements involving early asset commercialization strategy, market assessment, demand generation, forecasting, and oncology market research for early-stage assets.

Horsham, PA

• Contributed as a senior leader to a US-based consulting practice team, focusing on oncology early-stage commercialization portfolio assessment and market access strategic recommendations.
• Led deliverables for major pharmaceutical and healthcare technology companies, including Celgene, Johnson & Johnson, BMS, and Genmab.
• Secured and executed a $225,000 commercial consulting engagement for a biologic treatment for multiple myeloma, providing clinical perspectives, demand generation forecasts, and commercial strategy recommendations from.

Summit, NJ

• Served as the Global Marketing Lead for Abraxane (acquired from Abraxis Bioscience) and early-stage drugs targeting Non-Small Cell Lung Cancer (NSCLC).
• Led the global launch of Abraxane for NSCLC following Celgene's acquisition, coordinating efforts across cross-functional teams, including Clinical, Regulatory, and US Marketing.
• Directed project management planning for global launch readiness, ensuring seamless execution and alignment across all departments.
• Oversaw agency selection for strategic and advertising needs, driving the brand's global positioning and market strategy.
• Spearheaded early-stage commercialization efforts for Phase I assets, including opportunity assessment and providing input into clinical development strategies.
• Developed and maintained Key Opinion Leader relationships including multiple engagements in advisory boards and Key Congresses and Organizations (ASCO, ESMO, IASLC)

Montville, NJ

• Led the global brand strategy for PTK-ZK (in partnership with Novartis) and Tocosol paclitaxel (in joint venture with Sonus Pharmaceuticals).
• Directed global Phase 3 commercialization strategy for PTK-ZK, coordinating closely with Novartis to align on joint development goals.
• Managed cross-functional teams, including Clinical, Regulatory, Regional Marketing, and partners from Novartis and Sonus Pharmaceuticals, to ensure seamless collaboration and execution.
• Led project management efforts focused on the preparation and release of Phase 3 data, driving strategic decisions for global market entry.

Wilmington, DE

• Led the US life cycle strategy for IRESSA® (in partnership with global marketing) to align on joint development goals.
• Managed US based cross-functional teams, including Clinical, Regulatory, and Global partners to ensure seamless collaboration and execution.
• Led project management efforts focused on the market sizing and opportunity, scientific collaboration and KOL management driving strategic decisions for additional clinical indications (colorectal and breast cancer)
• Planned and executed Speakers Bureau for NSCLC launch
• Responsible for developing and maintaining KOL relationships in multiple tumor types including NSCLC, CRC, and Breast Cancer

New Brunswick, NJ

• Centocor, Inc. (renamed Janssen Pharmaceuticals) Malvern, PA, 2001 - 2002Manager, Global Strategic Marketing
• Developed commercialization plan for DNA based vaccine for breast and prostate cancer. Directed external consultants, medical communications and market research agencies to develop publication strategy for oncology.
• Supported licensing and development team by directing competitive intelligence activities to support Zarnestra™ (oral FT inhibitor for cancer treatment), manage pre-launch medical education initiatives, and perform due.
• Lead analyst on Doxil review which resulted in company acquisition

Raritan, New Jersey, United States

Sold Procrit™ and Duragesic™ in Philadelphia hospital territory. Accounts included Fox Chase, Hahnemann, Temple, and Pennsylvania Hospital. Finished top tier performer nationwide, achieved 160% sales growth ($1.2M) in one year ($3.2M total sales), Philadelphia district awarded 2nd and 3rd place finish nationwide on growth and revenue.

Collegeville, Pennsylvania, United States

• Executed clinical operations for Phase II and Phase III studies including protocol design, case report form design, Contract Research Organization (CRO) selection, clinical data review, and clinical study report
• Managed US based CRO vendor, including training, compliance, auditing, and budget
• Co-authored Clinical Study reports (Phase II and Phase III) and supporting clinical materials
• Supported creation of clinical portion of New Drug Application (NDA) filing

Master Of Business Administration - Mba, Pharmaceutical Marketing

Bachelor Of Science - Bs, Biochemistry

Activities and Societies: Kappa Sigma